CGON
NASDAQCG Oncology Inc.
Price$78.97-0.44 (-0.55%)
01:30 PM07:45 PM
News · 26 weeks53+75%
2026-03-012026-08-23
Mix2890d
- Insider13(46%)
- SEC Filings9(32%)
- Other6(21%)
Latest news
25 items- INSIDERDirector Post Leonard E sold $74,540 worth of shares (1,000 units at $74.54) as part of a pre-agreed trading plan and exercised 1,000 shares at a strike of $0.60 (SEC Form 4)4 - CG Oncology, Inc. (0001991792) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by CG Oncology Inc.SCHEDULE 13G/A - CG Oncology, Inc. (0001991792) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by CG Oncology Inc.SCHEDULE 13G/A - CG Oncology, Inc. (0001991792) (Subject)
- SECSEC Form 10-Q filed by CG Oncology Inc.10-Q - CG Oncology, Inc. (0001991792) (Filer)
- SECCG Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - CG Oncology, Inc. (0001991792) (Filer)
- PRCG Oncology Reports Second Quarter 2026 Financial Results and Provides Business UpdatesPIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected fourth quarter 2026 Phase 3 BOND-003 Cohort C Study Results published in The Lancet Oncology, further validating the strength of the clinical evidence supporting cretostimogene Well-positioned to deliver on key milestones with approximately $1.0 billion cash, cash equivalents and marketable securities sufficient to fund operations through 2029 DALLAS, Texas, Aug. 06, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON) today reported financial results for the second quarter ended June 30
- SECSEC Form 424B5 filed by CG Oncology Inc.424B5 - CG Oncology, Inc. (0001991792) (Filer)
- PRCG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet OncologyDALLAS, July 27, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON) today announced the publication of results from the pivotal Phase 3 BOND-003 Cohort C trial evaluating cretostimogene grenadenorepvec monotherapy in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without Ta/T1 disease, in The Lancet Oncology. "Patients with BCG-unresponsive NMIBC often face the difficult decision between pursuing additional bladder-sparing therapies or undergoing a severe, life-altering cystectomy," said Mark D. Tyson II, M.D., M.P.H., Mayo Clinic, and lead author of the publication. "The results f
- INSIDERDirector Post Leonard E exercised 1,000 shares at a strike of $0.60 and sold $71,170 worth of shares (1,000 units at $71.17) as part of a pre-agreed trading plan (SEC Form 4)4 - CG Oncology, Inc. (0001991792) (Issuer)
- INSIDERDirector Mulay James exercised 24,165 shares at a strike of $26.63 and sold $1,816,241 worth of shares (24,165 units at $75.16) as part of a pre-agreed trading plan (SEC Form 4)4 - CG Oncology, Inc. (0001991792) (Issuer)
- SECSEC Form 144 filed by CG Oncology Inc.144 - CG Oncology, Inc. (0001991792) (Subject)
- SECSEC Form 144 filed by CG Oncology Inc.144 - CG Oncology, Inc. (0001991792) (Subject)
- INSIDERDirector Liu Brian Guan-Chyun bought $24,814,454 worth of shares (371,085 units at $66.87) (SEC Form 4)4 - CG Oncology, Inc. (0001991792) (Issuer)
- INSIDERDirector Post Leonard E exercised 5,000 shares at a strike of $0.60 and sold $350,000 worth of shares (5,000 units at $70.00) as part of a pre-agreed trading plan (SEC Form 4)4 - CG Oncology, Inc. (0001991792) (Issuer)
- PRThe New War on Cancer: Four Public Companies Helping Lead a Medical RevolutionDENVER, June 25, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – Cancer treatment is undergoing one of the most significant transformations in modern medical history. For decades, physicians relied primarily on surgery, radiation, and chemotherapy. While those therapies have saved countless lives, a new generation of biotechnology companies is working to make cancer treatment smarter, more targeted, and potentially more effective. Rather than simply attacking rapidly dividing cells, researchers are developing therapies designed to identify specific genetic mutations, harness the immune system, and deliver treatments directly to cancer cells while minimizing damage to healthy tissue. Seve
- SECSEC Form 144 filed by CG Oncology Inc.144 - CG Oncology, Inc. (0001991792) (Subject)
- INSIDERDirector Post Leonard E sold $325,000 worth of shares (5,000 units at $65.00) as part of a pre-agreed trading plan and exercised 5,000 shares at a strike of $0.60 (SEC Form 4)4 - CG Oncology, Inc. (0001991792) (Issuer)
- SECSEC Form 144 filed by CG Oncology Inc.144 - CG Oncology, Inc. (0001991792) (Subject)
- INSIDERDirector Mulay James exercised 1,964 shares at a strike of $9.64 and sold $118,076 worth of shares (1,964 units at $60.12) as part of a pre-agreed trading plan (SEC Form 4)4 - CG Oncology, Inc. (0001991792) (Issuer)
- SECSEC Form 8-K filed by CG Oncology Inc.8-K - CG Oncology, Inc. (0001991792) (Filer)
- INSIDERSEC Form 4 filed by Director Liu Brian Guan-Chyun4 - CG Oncology, Inc. (0001991792) (Issuer)
- INSIDERSEC Form 4 filed by Director Tong Victor Edward Jr4 - CG Oncology, Inc. (0001991792) (Issuer)
- INSIDERSEC Form 4 filed by Director Mulay James4 - CG Oncology, Inc. (0001991792) (Issuer)
- INSIDERSEC Form 4 filed by Director Graf Susan E4 - CG Oncology, Inc. (0001991792) (Issuer)
- INSIDERSEC Form 4 filed by Director Rossi Christina4 - CG Oncology, Inc. (0001991792) (Issuer)
CGON FAQ
6 questionsWhere does CGON stock trade?
CG Oncology Inc. (CGON) is listed on NASDAQ.What sector and industry is CGON in?
CG Oncology Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did CG Oncology Inc. go public?
CG Oncology Inc. (CGON) completed its IPO in 2024.What are analysts saying about CGON?
CG Oncology Inc. has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Peer Perform on 2026-05-19. Recent price targets range from $2300.00 to $4100.00.What companies are similar to CGON?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare CGON side-by-side with any of them on Quantisnow.How can I track CGON on Quantisnow?
Quantisnow aggregates CG Oncology Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CGON to receive live email and push alerts on every new disclosure.